Therefore, targeting PD-1/PD-L1 signaling using immune checkpoint inhibitors (ICIs) such as anti-PD-1 antibodies (nivolumab and pembrolizumab) has provided remarkable therapeutic benefits in the treatment of various cancers [4]. This evidence concerns the gene CD274 and cancer.